Reduced Hospital Costs for Ultrasound-guided Vacuum-assisted Excision Compared with Open Surgery in Patients with Benign Breast Masses and High-risk Lesions. Issue 5 (24th July 2020)

• Record Type: Journal Article
• Authors: Whitworth, Pat; Hogan, Andrew; Ferko, Nicole; Son, Daniel; Wang, Faye; Xiong, Yan; Suri, Himanshu; Barclay, Ben
• Is Part Of: Journal of breast imaging. Volume 2:Issue 5(2020)
• Page Start: 452
• Page End: 461
• Publication Date: 2020-07-24
• Subjects: benign -- breast lesion -- vacuum-assisted excision -- open surgical excision -- cost; Breast -- Imaging -- Periodicals; Breast -- Cancer -- Diagnosis -- Periodicals; 616.994490
• DOI: 10.1093/jbi/wbaa055
• Languages: English
• ISSNs: 2631-6110

Abstract

Abstract: Objective: Benign breast masses represent a substantial proportion of breast cancer screening results and may require multiple follow-up visits and biopsy. Even with a preceding benign core biopsy, benign masses have been excised via open surgery for a variety of reasons. This study compared the procedural costs of US-guided vacuum-assisted excision (US-VAE) versus open surgical excisions for benign breast masses and high-risk lesions (HRL). Methods: In this retrospective cohort study, female outpatients receiving US-VAE or open excision of benign breast masses between 2015 and 2018 were identified within the Premier Healthcare Database. A secondary analysis was conducted for patients with HRLs. Propensity score matching and multivariate regression adjusted for patient demographics, encounter level covariates, and hospital characteristics. The total procedural costs were reported from a hospital perspective. Results: A total of 33 724 patients underwent excisions for benign breast masses (8481 US-VAE and 25 242 open surgery). Procedural costs were significantly lower in unmatched patients who received US-VAE ($1350) versus open surgery ($3045) ( P < 0.0001). After matching, a total of 5499 discharges were included in each group, with similar findings for US-VAE ($1348) versus open surgery ($3101) ( P < 0.0001). A secondary analysis of matched HRL patients (41 discharges in each group) also showed significantly lower procedural costs with US-VAE ($1620) versus open surgery ($3870) ( P < 0.0001). Conclusion: Among patients with benign breast masses or HRLs, US-VAE was associated with significantly lower procedural costs versus open surgery. If excision is performed and expected clinical outcomes are equal, US-VAE is preferable to reduce costs without compromising the quality of care.